Free preview

Managing children living with HIV/AIDS

DN 223 · Surgical nursing (III) and Paediatric nursing (II) — Diploma Nursing - Direct

Learning objectives

  • Introduction to HIV/AIDS in children
  • Clinical manifestation of HIV/AIDS in children
  • Opportunistic infections in children
  • Treatment of HIV/AIDS in children (ARV therapy)
  • Prevention and control of HIV/AIDS
  • Counselling in HIV/AIDS

Introductory study notes

Introduction to HIV/AIDS in children

Definition

HIV (human immunodeficiency virus) is a retrovirus that infects and destroys CD4 T-lymphocytes, causing progressive immune deficiency. AIDS is the advanced stage (WHO clinical stage 4 or severe immunosuppression). HIV-1 causes most infections; HIV-2 is less virulent and mainly found in West Africa.

Replication

HIV binds CD4 receptors, enters the cell, and its enzyme reverse transcriptase converts viral RNA into DNA, which integrase inserts into the host genome; protease then assembles new virions. Antiretroviral drugs block these steps.

Transmission

  • In children, mainly mother-to-child transmission (MTCT) – during pregnancy, labour/delivery and breastfeeding. Without intervention, most MTCT occurs during labour and delivery.
  • Other routes: sexual (adolescents, sexual abuse), blood transfusion, unsterile needles/instruments.
  • Infectious fluids: blood, semen, vaginal fluid, breast milk.
  • Not spread by hugging, sharing utensils, toilets, mosquitoes.

Natural history in children

Disease progresses faster in infants than in adults because of an immature immune system; without treatment many die before 2 years. Children are staged using the WHO clinical staging (4 stages). CD4 is expressed as a percentage under 5 years. Viral load measures the number of virus copies in the blood.

Diagnosis

  • Under 18 months: DNA PCR (early infant diagnosis), because maternal antibodies cross the placenta and make antibody tests unreliable. First PCR at 6 weeks (or first contact); repeat as per guidelines.
  • 18 months and above: rapid antibody tests (national algorithm).
  • A breastfed HIV-exposed infant's final status is confirmed after breastfeeding ends (at 18 months or 6 weeks after stopping, whichever is later).
  • Window period – time after infection before antibodies are detectable.

Infection prevention in care

Standard (universal) precautions: treat all blood and body fluids as potentially infectious – gloves, safe sharps disposal, hand hygiene.

Nursing process (overview)

Nursing diagnosis

Goal

Interventions

Rationale

Risk for infection

Infections prevented

Cotrimoxazole prophylaxis, immunisation, hygiene

Immune deficiency

Deficient knowledge (caregivers)

Understands HIV

Explain transmission, testing, treatment

Reduces stigma, promotes care

Risk for delayed growth

Normal growth

Growth monitoring, nutrition support, early ART

HIV causes failure to thrive

Antiretroviral therapy (ART) in children

Principles

  • Test and treat: start ART in all HIV-infected children as soon as possible, regardless of CD4 or stage.
  • Use at least three active drugs to suppress viral replication and prevent resistance.
  • Aim: suppress viral load, restore immunity, normal growth and development.
  • ART is lifelong; doses are adjusted by weight band as the child grows.

Drug classes

Drug

Class

Key adverse effects

Abacavir (ABC)

NRTI

Hypersensitivity (fever, rash, GI and respiratory symptoms) – stop and never re-challenge

Lamivudine (3TC)

NRTI

Well tolerated

Zidovudine (AZT)

NRTI

Anaemia, neutropenia

Tenofovir (TDF)

NRTI

Renal toxicity, bone loss

Nevirapine (NVP)

NNRTI

Rash, hepatotoxicity

Efavirenz (EFV)

NNRTI

CNS effects – dizziness, vivid dreams

Lopinavir/ritonavir (LPV/r)

Protease inhibitor

GI upset; syrup needs refrigeration

Dolutegravir (DTG)

Integrase inhibitor

Insomnia, headache; weight gain

Preferred first-line for children (Uganda/WHO): ABC + 3TC + DTG (paediatric DTG formulations); adolescents/adults: TDF + 3TC + DTG.

Interactions

  • DTG with antacids, iron, calcium or zinc: give DTG 2 hours before or 6 hours after them.
  • Rifampicin lowers DTG levels – give DTG twice daily during TB treatment.

Monitoring

Viral load at 6 months after starting, then routinely (every 6–12 months). Adherence >95% is needed. A high viral load (≥1000 copies/mL) → intensive adherence counselling (3 sessions) and repeat viral load after 3 months; switch to second line only if still high (treatment failure).

Nursing process

Assessment

Weight (for dosing), adherence (pill counts, caregiver report), side effects, viral load results, disclosure status.

Nursing care plan

Nursing diagnosis

Goal

Interventions

Rationale

Risk for non-adherence

>95% adherence

Treatment supporter, reminders, palatable formulations, explain missed-dose rule (take as soon as remembered unless close to the next dose)

Prevents resistance

Risk for adverse drug effects

Early detection

Teach and monitor side effects; Hb on AZT, renal function on TDF

Safety

Deficient knowledge

Caregiver competent

Weight-band dosing, storage, age-appropriate disclosure to the child

Long-term success

Evaluation

Suppressed viral load, good growth, no serious side effects.

Sample questions

Question 1. A 9-year-old on ABC/3TC/DTG has a viral load of 15,000 copies/mL. His mother says he often spits out his medicine and misses doses. The nurse should:

  • A. Switch him to second-line immediately
  • B. Stop ART
  • C. Start intensive adherence counselling, address the barriers, and repeat the viral load after 3 months
  • D. Double his doses

Question 2. Without intervention, most mother-to-child transmission occurs during:

  • A. Labour and delivery
  • B. Early pregnancy
  • C. Weaning
  • D. Conception

Question 3. When a child on DTG starts rifampicin-based TB treatment:

  • A. DTG is stopped
  • B. Rifampicin is stopped
  • C. Nothing changes
  • D. DTG is given twice daily

Question 4. Three weeks after starting ART, a child who recently began TB treatment develops worsening fever, larger neck nodes and more cough. The nurse should:

  • A. Stop ART because of drug resistance
  • B. Treat it as a new infection only
  • C. Recognise likely IRIS – continue ART and TB treatment and report for review (steroids may be needed)
  • D. Record ART failure and stop all drugs

Question 5. For a low-risk HIV-exposed infant, nevirapine is given for:

  • A. 1 day
  • B. 1 year
  • C. Until 18 months
  • D. 6 weeks